Kyle Gano
Fortuna: 24 M $ al 31/08/2026
Fortuna: 24 M $ al 31/08/2026
Kyle W.
Gano is currently President, Chief Executive Officer & Director at Neurocrine Biosciences, Inc. since 2024.
Dr. Gano is also a Director at Pharmaceutical Research & Manufacturers of America since 2024.
Education history includes an undergraduate degree from the University of Washington in 1996, an MBA and a doctorate from the University of California, Los Angeles, and an undergraduate degree from the University of Oregon.
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 11/09/2026 | 154.728 ( 0,15 % ) | 24 M $ | 31/08/2026 |
| Empresas | Cargo | Inicio |
|---|---|---|
| NEUROCRINE BIOSCIENCES, INC. | Director Ejecutivo | 11/10/2024 |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Director/Miembro de la Junta | 01/10/2024 |
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
| Empresas privadas | 5 |
|---|---|
Neurocrine Biosciences, Inc.
Neurocrine Biosciences, Inc. BiotechnologyHealth Technology Discovers, develops and commercializes treatments for neurological, neuroendocrine and neuropsychiatric disorders | Health Technology |
University of Washington
University of Washington Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of California, Los Angeles
University of California, Los Angeles Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Oregon
University of Oregon Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Pharmaceutical Research & Manufacturers of America
Pharmaceutical Research & Manufacturers of America BiotechnologyHealth Technology Provides pharmaceutical research and biotechnology services | Health Technology |
Selecciona tu edición
Toda la información financiera adaptada al ámbito nacional.